ARTICLE IN PRESSTHE JOURNAL0UROLOGYCheck forAUA Guideline Articlewww.auajournals.ong/journal/juroupdatesUpdates to Advanced Prostate Cancer:AUA/SUOGuideline (2023)William Lowrance,1*Robert Dreicer,2 David F.Jarrard,3 Kristen R.Scarpato,4 Sennett K.Kim,5Erin Kirkby,David I.Buckley,Jessica C.Griffin,and Michael S.CooksonBon Secours Mercy Health,Greenville,South Carolina2University of Virginia Medical School Charlottesville,VirginiaUniversity of Wisconsin School of Medicine,Madison,Wisconsin"Vanderbilt University Medical Center,Nashville,TennesseeAmerican Urological Association,Linthicum,MarylandOregon Health Science University,Pacific Northwest Evidence-based Practice Center,Portland,Oregon7University of Oklahoma College of Medicine,Oklahoma City,OklahomaPurpose:In 2022 the American Urological Association (AUA)requested anUpdated Literature Review (ULR)to incorporate new evidence generated sincethe 2020 publication of this guideline.The resulting 2023 Guideline Amendmentaddresses updated recommendations for patients with advanced prostate cancer.Materials and Methods:The ULR addressed 23 of the original 38 guidelinestatements and included an abstract-level review of eligible studies publishedsince the 2020 systematic review.Sixteen studies were selected for full text re-view.The current report presents the updates made to the Guideline as a resultof that new literature.Results:The Advanced Prostate Cancer Panel amended evidence-and consensus-based statements based on an updated review to aid clinicians in the managementof patients with advanced prostate cancer.These statements are summarized inFigure and detailed herein.Conclusion:This Guideline Amendment provides a framework designed toimprove a clinician's ability to treat patients diagnosed with advanced prostatecancer with the most current evidence-based information.Further research andpublication of high-quality clinical trials will be essential to continue to improvethe quality of care for these patients.Key Words:metastasis,prostate cancer,mHSPC,mCRPC,ADT,MDT,cancer,men,advancedBACKGROUNDnew diagnoses of prostate cancer and34,700 deaths are estimated in the U.S.EpidemiologyinProstate cancer is the most common solid2023.The incidence of prostateorgan malignancy for men in the U.S.cancer is 70%higher in Black men asand remains the second leading causecompared to White men for reasonsof cancer deaths for this populationthat remain unclear.Importantly,the(Figure).In fact,approximately 288,300incidence of advanced stage diseaseSubmitted March 27.2023:accepted Mach 28.2023:published 000The complete unabridged version of the guideline is available atThis document is being printed as submitted,independent of standad editorial or peer review by the editors of The Joumnal of Urobgy.*Correspondence:Bon Secours Mercy Health.104 Innovation Dr,Greenville,SC 29607(telephone:864-603-6300:emait:will_lwrance@bshsi.orgl.THE JOURNAL OF UROLOGYhttp5:/∥doi.org/10.1097/JU.00000000000034522023 by AMERICAN UROLOGICA
